1. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 2008;74:158–169.
2. Krell D, Stebbing J. Aristolochia: the malignant truth. Lancet Oncol 2013;14:25–26.
3. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387–391.
4. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686–1692.
6. Gokmen MR, Cosyns JP, Arlt VM, et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 2013;158:469–477.
8. Lord GM, Tagore R, Cook T, Gower P, Pusey CD. Nephropathy caused by Chinese herbs in the UK. Lancet 1999;354:481–482.
9. Tanaka A, Nishida R, Maeda K, Sugawara A, Kuwahara T. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acids cause a different type of Chinese herb nephropathy? Clin Nephrol 2000;53:301–306.
10. Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis 2000;35:313–318.
11. Lee S, Lee T, Lee B, et al. Fanconi’s syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid. Nephrology (Carlton) 2004;9:126–129.
12. Laing C, Hamour S, Sheaff M, Miller R, Woolfson R. Chinese herbal uropathy and nephropathy. Lancet 2006;368:338.
13. Chau W, Ross R, Li JY, Yong TY, Klebe S, Barbara JA. Nephropathy associated with use of a Chinese herbal product containing aristolochic acid. Med J Aust 2011;194:367–368.
14. Hutton H, Dowling J, Kerr P. Acute renal failure due to an aristolochic acid containing herbal remedy. Nephrology (Carlton) 2012;17:522–523.
15. Tazi I, Nafil H, Mahmal L. Fatal renal failure due to self administration of Aristolochia Longa after treatment with chemotherapy. Arab J Nephrol Transplant 2012;5:54.
16. Vaclavik L, Krynitsky AJ, Rader JI. Quantification of aristolochic acids I and II in herbal dietary supplements by ultra-high-performance liquid chromatography-multistage fragmentation mass spectrometry. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2014;31:784–791.
17. Jeong HJ, Choi KH, Park JH, et al. Nephropathies associated with herb medicine ingestion. Kidney Res Clin Pract 1996;15:365–372.
18. Nam KD, Lee TW, Noh JH, et al. A case of Chinese herbs nephropathy. Korean J Nephrol 2000;19:751–755.
19. Choi CR, Yun YW, Lee DK, et al. A case of Fanconi’s syndrome due to Chinese herb nephropathy: differences between European and Asian CHN. Korean J Nephrol 2003;22:118–123.
20. Lee JW, Sohn MJ, Heo NJ, et al. A case of Chinese herb nephropathy induced by Aristolochia fangchi. Korean J Med 2006;71:224–228.
21. Sung HY, Shin SJ, Son SW, et al. Chinese Herbs induced end-stage renal disease in a patient with minimal change nephrotic syndrome. Korean J Nephrol 2006;25:99–102.
22. Won HS, Cho IJ, Yoo SH, et al. A case of Fanconi’s syndrome due to Chinese herb nephropathy. Ewha Med J 2007;30:101–105.
23. Luciano RL, Perazella MA. Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. Drug Saf 2015;38:55–64.
24. Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int 2008;73:595–607.
27. Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer 2013;133:14–20.
28. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Steroid therapy in chronic interstitial renal fibrosis: the case of Chinese-herb nephropathy. Nephrol Dial Transplant 2002;17:2033–2034.